¼¼°è ÃÖ°í ±Û·Î¹ú Á¦¾à»ç°¡ ¸ô·Á¿Â´Ù

ÆÄ¿öÄÚ¸®¾Æl½ÂÀÎ2012.02.03l¼öÁ¤2012.02.06 10:41

Å©°Ô

ÀÛ°Ô

¸ÞÀÏ

Àμâ

½Å°í

»çÁø2 copy.jpg


ÀüÀÓ»ó ½Å¾à°³¹ß Ç÷§Æû ¾Æ¹ÙŸ¸¶¿ì½º ½Ã½ºÅÛÀ¸·Î

¼¼°è ÃÖ°í ±Û·Î¹ú Á¦¾à»ç°¡ ¸ô·Á¿Â´Ù

- »ï¼º¼­¿ïº´¿ø ³­Ä¡¾Ï¿¬±¸»ç¾÷´Ü, ¹Ì±¹ ·¹±Ö·¯½º»ç ½Å±Ô ³úÁ¾¾çÄ¡·áÁ¦ Æò°¡


The World Leading Global Pharmaceutical Firms Rush into the Korean Drug Market

with Pre-clinical New Drug Discovery Platform, AVATA MOUSE System

-  Institute for Refractory Cancer Research, Samsung Medical Center, evaluating new brain tumor treatments


»ï¼º¼­¿ïº´¿ø ³­Ä¡¾Ï¿¬±¸»ç¾÷´Ü(´ÜÀå ³²µµÇö)Àº 12¿ù 13ÀÏ, ¸¶ÀÌÅ©·ÎRNA Ä¡·áÁ¦ ºÐ¾ßÀÇ ¼±µÎ±â¾÷ÀÎ ¹Ì±¹ ·¹±Ö·¯½º»ç¿Í »ï¼º¼­¿ïº´¿øÀÌ º¸À¯ÇÏ°í ÀÖ´Â ÃÖ÷´Ü ¿¬±¸¸ðµ¨ÀÎ ¡®¾Æ¹ÙŸ ¸¶¿ì½º¡¯¸¦ ±â¹ÝÀ¸·Î ÇÏ´Â 100¸¸´Þ·¯ ±Ô¸ðÀÇ °øµ¿¿¬±¸Çù·Â °è¾àÀ» ü°áÇÏ´Â µî ¼¼°èÀû À¯¼ö Á¦¾à»ç ¹× »çȸ´Üü·ÎºÎÅÍ Å« °ü½É°ú ¿¬±¸Çù·Â Á¦¾È¹Þ°í ÀÖ´Ù°í ¹àÇû´Ù. »ï¼º¼­¿ïº´¿ø ³­Ä¡¾Ï»ç¾÷´ÜÀÌ Áö³­ÇغÎÅÍ À̹ø °Ç±îÁö ¸ÓÅ©, È­ÀÌÀÚ, ³Ø½ºÁ¦³Ø½º µî ±Û·Î¹úÁ¦¾à»ç¿Í ÃÑ 30¾ï¿ø ±Ô¸ðÀÇ ¿¬±¸Çù¾àÀ» ü°áÇß´Ù. À̹ø¿¡ Çù¾àÀ» ü°áÇÑ ·¹±Ö·¯½º»ç´Â ¸¶ÀÌÅ©·ÎRNA¸¦ È°¿ëÇÑ Ç×¾ÏÁ¦ °³¹ß¿¡ °í½ÉÇØ¿À´ø Â÷¿¡ ¿ÃÇØ ÃÊ È­ÀÌÀÚÀÇ Ç×¾ÏÁ¦ °³¹ß ¼öÀåÀÎ ´Ò ±é½¼ ¹Ú»ç¸¦ ¿µÀÔÇѵ¥ ÀÌ¾î ¼¼°èÀûÀ¸·Îµµ ÃÖ÷´Ü ½Ã½ºÅÛÀÎ Àü(îñ)ÀÓ»ó Áß°³¿¬±¸ Ç÷§ÆûÀÎ ¡®¾Æ¹ÙŸ ¸¶¿ì½º¡¯¸¦ °®Ãá »ï¼º¼­¿ïº´¿ø°ú ¿¬±¸Çù¾àÀ» ü°áÇÔÀ¸·Î½á, ÇâÈÄ ³úÁ¾¾ç ¸ÂÃã Ä¡·áÁ¦¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ ¼ö ÀÖ°Ô µÆ´Ù°í ¹àÇû´Ù. »ï¼º¼­¿ïº´¿øÀÇ ¾Æ¹ÙŸ ¸¶¿ì½º´Â ³úÁ¾¾ç ȯÀÚ¿¡°Ô ¾òÀº Á¶Á÷À» ¸é¿ª¼ºÀÌ ³·Àº ½ÇÇèÁã¿¡ À̽ÄÇÏ¿© Å°¿î Á㸦 ¸»ÇÑ´Ù. ¾Æ¹ÙŸ ¸¶¿ì½ºÀÇ Á¾¾çµµ ȯÀÚ¿¡¼­ ÀÚ¶ó´Â ¾ÏÁ¶Á÷°ú À¯ÀüÀû, Á¶Á÷ÇÐÀûÀ¸·Î °°Àº Ư¼ºÀ» Áö´Ï°í Àֱ⿡ ȯÀÚÀÇ ÀÓ»ó»óŸ¦ °¡Àå Àß ´ëÇ¥Çϸç, À̸¦ ±â¹ÝÀ¸·Î ÀÓ»ó½ÃÇè Àü¿¡ ¹Ì¸® ÀÎü¿¡¼­ÀÇ È¿°ú¸¦ ¿¹»óÇÒ ¼ö ÀÖ¾î ½Å¾à°³¹ßÀÇ ¼º°ø°¡´É¼ºÀ» ³ô¿©ÁÙ °ÍÀ¸·Î ¿¹»óÇÏ´Â ÃÖ÷´Ü ¿¬±¸¸ðµ¨ÀÌ´Ù.


±Û·Î¹ú Á¦¾à»ç¸¦ ¶Ù¾î³Ñ´Â Ç×¾Ï Á¦¾à »ê¾÷ÀÇ Åº»ý ±â´ë

 ¾Ç¼º ³úÁ¾¾çÀº ÇöÀç±îÁö ¹ßº´ÇÏ¸é °æ°ú°¡ ³ª»Ú°í Ä¡·á ¹æ¹ýÀÌ ¾ø´Â ³­Ä¡¼º ÁúȯÀ¸·Î ȯÀÚµé°ú °¡Á·, ÀÇ»çµéÀº »õ·Î¿î Ä¡·áÁ¦ °³¹ßÀ» ¾ÖŸ°Ô ±â´Ù¸®°í ÀÖ´Â ½ÇÁ¤ÀÌ´Ù. À̹ø¿¡ °³¹ßÁßÀÎ »õ·Î¿î Ä¡·áÁ¦´Â ¸¶ÀÌÅ©·Î RNAÀÇ À¯ÀüÀÚ ¹ßÇö Á¶ÀýÀ» ÅëÇØ ³úÁ¾¾ç¼¼Æ÷ÀÇ ¼ºÀå°ú ÀüÀ̸¦ ¾ïÁ¦ÇÏ¿© ³úÁ¾¾ç Ä¡·á¿¡ È¿°úÀûÀÏ °ÍÀ¸·Î ±â´ëÇÏ°í ÀÖ´Ù. °øµ¿¿¬±¸Çù·Â ¼Ò½ÄÀ» µéÀº ¹Ì±¹ÀÇ ABC2(Accelerate Brain Cancer Cure)´Â ÀÌ ¿¬±¸¿¡ Áö¿øÀǻ縦 ¹àÇô ¿Ô´Ù. ABC2 ´Üü´Â 2001³â ¼³¸³µÈ ´Üü·Î, 2002³â ³úÁ¾¾çÀ¸·Î »ç¸ÁÇÑ ´í ÄÉÀ̽º(Dan Case)°¡ Á¶¼ºÇÑ ±â±ÝÀ¸·Î ¿î¿µµÇ¸ç, Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ ±× ½Ã´ëÀÇ °¡Àå ¼±µµÀûÀÎ ÀÇ»ç, ±â¾÷, ¿¬±¸ÀÚ¸¦ Áö¿øÇÏ´Â °ÍÀ¸·Î Àß ¾Ë·ÁÁ® ÀÖ´Ù. ´í ÄÉÀ̽º(Dan Case)´Â ¿ì¸®¿¡°Ôµµ Àß ¾Ë·ÁÁø H&Q(Çö JP Morgan¿¡ ÇÕº´)ÀÇ È¸ÀåÀ¸·Î »ýÀü¿¡µµ ¹°·ÐÀÌ°í ÇöÀç ±× ÈÄÀÓÀÚ ¿ª½Ã ³úÁ¾¾ç Ä¡·á¸¦ À§ÇÑ »çȸ Áö¿ø¿¡ Èû¾²°í ÀÖ´Ù. À̹ø °è¾à ü°áÀ» ºñ·ÔÇÏ¿© ³­Ä¡¾Ï»ç¾÷´Ü¿¡¼­´Â ¾Æ¹ÙŸ¸¶¿ì½º ½Ã½ºÅÛÀ» È°¿ëÇÏ¿© ¸ÓÅ©, È­ÀÌÀÚ, ³Ø½ºÁ¦³Ø½º µî ±Û·Î¹úÁ¦¾à»ç¿ÍÀÇ ¿¬±¸Çù·Â°è¾àÀ» ÅëÇØ ½Å±Ô ½Å¾àÈĺ¸¹°ÁúÀ» Æò°¡ÇÏ°í ÀÖ°í, ±× ¿Ü ±¹³»¿Ü ¹ÙÀÌ¿ÀÁ¦¾à»ç¿Í È°¹ßÇÑ °øµ¿¿¬±¸¸¦ °èȹÇÏ°í ÀÖ´Ù. ¿¬±¸°¡ ÁøÇàµÉ¼ö·Ï ±¹³»¿¡¼­µµ Ç׾ϽžàÀ» °³¹ßÇÏ°Ú´Ù´Â ÀÇÁö°¡ Ä¿Áö°í ÀÖ´Ù. »ç¾÷´ÜÀå ³²µµÇö ±³¼ö´Â "³­Ä¡¾Ï¿¬±¸»ç¾÷´ÜÀº º¸°Çº¹ÁöºÎ°¡ Áö¿øÇÏ´Â ¼±µµÇü Ư¼ºÈ­ ¿¬±¸»ç¾÷ÀÇ ÀÏȯÀ¸·Î, ±¹³»¿¬±¸±â°ü, ´ëÇÐÀÇ ¼¼°èÀû ¼öÁØÀÇ ¿¬±¸´É·ÂÀ» ±â¹ÝÀ¸·Î À̹ø ¼º°ú¸¦ ³¾ ¼ö ÀÖ¾ú´Ù. ±Û·Î¹úÁ¦¾à»ç´Â ºñ´Ü ¾Æ¹ÙŸ¸¶¿ì½º½Ã½ºÅÛ»Ó ¾Æ´Ï¶ó, ½Å¾à °³¹ß ºÐ¾ß¿¡ ±Þ¼ÓÇÑ ¼ºÀåÀ» º¸ÀÌ´Â Çѱ¹À» ÁÖ¸ñÇÏ°í ÀÖ´Ù. ¸ÓÁö¾Ê¾Æ ¿ì¸®³ª¶ó¿¡¼­µµ ±Û·Î¹ú Á¦¾à»ç¸¦ ¶Ù¾î³Ñ´Â Ç×¾Ï Á¦¾à »ê¾÷ÀÇ Åº»ýÀ» ±â´ëÇØ º¼ ¼ö ÀÖÀ» °Í¡±À̶ó°í ¹àÇû´Ù. 




On December 13, 2011, Institute for Refractory Cancer Research, Samsung Medical Center (Director Nam Do Hyun, SMC) has announced that they made a joint research agreement worth of one million dollar based on 'AVATA MOUSE', the latest research model which is held by Regulus. and SMC. Regulus is the American leading firm in the Micro RNA treatment industry. Lately the Institute has received several proposals on a joint research and considerable interests from the world class pharmaceutical companies and social groups. Since last year, SMC has made several join research agreements worth of 3 billion dollars in total with global pharmaceutical companies such as Merck and Pfizer. Regulus made an statement that they have attempted to develop anti-cancer drug using Micro RNA; as part of these efforts, they employed Dr. Nill Gibson, leader of anti-cancer drug developing at Pfizer early this year, then made an joint research agreement with SMC which is built with 'AVATA MOUSE' of pre-clinical translational research platform, the world latest system in a bid to accelerate the customized treatment development for brain tumor in the near future.

Avata Mouse of SMC means experimental mice with low immunity that are transplanted with the tissues of the patient with brain cancer. Avata Mouse's cancer retains the same traits regarding cancer tissue, genetics, and histology, representing most the clinical status of a patient so that this would the best way to expect what kind of effect would occur in the human body before a clinical experiment. In short, Avata Mouse is the latest research model that is likely to heighten the successful possibility of a new pharmaceutical development. 


Korea expects an Anti-Cancer Pharmaceutical Industry beyond a Global Pharma Firm

Up until now, a malignant brain tumor has been considered as a refractory disease where results in a severe and extreme conclusion, then there is no any treatment. Accordingly patients, their family, and doctors are desperately waiting for a new treatment. Lately, a new treatment under development is to adjust the emergency of gene of Micro RNA for the purpose of controlling the growth and transfer of a brain tumor cell; it is expected that the treatment would be effective to the treatment of a brain cancer. In the aftermath of the joint research, American ABC2 (Accelerate Brain Cancer Cure, ABC2) announced that they are willing to support the joint research.


 Since its launch in 2001 as a private group, ABC2 has been operated from the capitals fund-raised by Dan Case who was died of a brain cancer in 2002. ABC2 is known for its efforts to support the most innovative doctor, firm, and researcher of the day for a medical treatment development. Dan Case was a then chairman of H&Q (Merged to the current JP Morgan) which has been familiar to Koreans, being dedicated to a social support for the sake of a brain cancer treatment, then his successor also follows in his footsteps. On top of this joint research agreement, Institute for Refractory Cancer Research has evaluated potential materials for a new medical treatment using Avata Mouse System through the cooperative research agreement with some global pharma firms including Merck and Pfizer. Furthermore, the institute is slated to make  joint research agreements aggressively with domestic and overseas bio-pharmaceutical firms. As the research has seen its progress, the domestic industry also goes along with a new medical drug development for the anti-cancer. Professor Nam Do Hyun, director of the institute, stated, "Institute for Refractory Cancer Research was established as a part of advanced specialty research projects backed by Ministry of Health and Welfare. This achievement was made based on the world class research capability of domestic research institutions and universities. Avata Mouse System deserves to receive interests considerably from more and more global pharmaceutical firms; More importantly, they have paid attentions to the fast growth in the new medical treatment industry in Korea. It will not be long before for Korea to produce an anti-cancer pharmaceutical industry beyond a just global pharmaceutical firm"



ÆÄ¿öÄÚ¸®¾Æ  
<ÀúÀÛ±ÇÀÚ © ¿ù°£ÆÄ¿öÄÚ¸®¾Æ, ¹«´Ü ÀüÀç ¹× Àç¹èÆ÷ ±ÝÁö>

ÆÄ¿öÄÚ¸®¾ÆÀÇ ´Ù¸¥±â»ç º¸±â
°¡Àå ¸¹ÀÌ º» ±â»ç
¿©¹é
¿©¹é
½Å¹®»ç¼Ò°³¤ý±â»çÁ¦º¸¤ý±¤°í¹®ÀǤýºÒÆí½Å°í¤ý°³ÀÎÁ¤º¸Ãë±Þ¹æħ¤ýû¼Ò³âº¸È£Á¤Ã¥¤ýÀ̸ÞÀϹ«´Ü¼öÁý°ÅºÎ
¢ß´º½º¾Ø¸Å°ÅÁø ÆÄ¿öÄÚ¸®¾Æ ´ëÇ¥ ¹éÁ¾¿ø  |   ¼­¿ïƯº°½Ã ±¤Áø±¸ Á߰ 162-3¹øÁö 2Ãþ  |  ´ëÇ¥ÀüÈ­ : 02-466-5085  |  Æѽº : 02-444-0454
´ëÇ¥¸ÞÀÏ/Á¦ÈÞ±¤°í¹®ÀÇ : bridgekorea@naver.com  |  °³ÀÎÁ¤º¸°ü¸®Ã¥ÀÓÀÚ : ¹éÁ¾¿ø(bridgekorea@naver.com)  |  »ç¾÷ÀÚµî·Ï¹øÈ£ : 591-87-01957
û¼Ò³âº¸È£Ã¥ÀÓÀÚ : ¹éÁ¾¿ø
Disclaimer: PowerKorea makes an article based on the information of products and/or services provided in paper and/or in interview by the company, the organization or the person that is solely responsible for the information.
Copyright © 2008 - 2024 ¿ù°£ÆÄ¿öÄÚ¸®¾Æ. All rights reserved.